Target Name: CD300LF
NCBI ID: G146722
Review Report on CD300LF Target / Biomarker Content of Review Report on CD300LF Target / Biomarker
CD300LF
Other Name(s): CMRF35-like molecule 1 (isoform 3) | CD300LF variant 1 | immune receptor expressed on myeloid cells 1 | CD300 molecule like family member f | IREM-1 | CD300 molecule like family member f, transcript variant 3 | CD300 antigen-like family member F | Immunoglobulin superfamily member 13 | CMRF35-like molecule 1 | Inhibitory receptor IREM1 | CMRF35-like molecule 1 (isoform 1) | LMIR3 | immunoglobin superfamily member 13 | CD300 antigen like family member F | inhibitory receptor IREM1 | Iimmune receptor expressed on myeloid cells 1 | CLM-1 | IREM1 | immunoglobulin superfamily member 13 | CD300 molecule like family member f, transcript variant 1 | NKIR | Immunoglobin superfamily member 13 | Immune receptor expressed on myeloid cells 1 | CLM1 | CD300f | CLM1_HUMAN | CD300LF variant 3 | IgSF13 | CD300 molecule-like family member f | NK inhibitory receptor

CD300LF: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow, where white blood cells called leukemia cells overgrow. This type of cancer is often treated with chemotherapy, bone marrow transplantation, or targeted therapies. While these treatments can be effective in managing the disease, they often come with side effects and a low response rate. Therefore, there is a need for new treatments that can provide more effective relief from the symptoms associated with CML.

CD300LF: A Potential Drug Target

One potential drug target for CML is the protein CD300LF (ISOFORM 3). CD300LF is a protein that is expressed in the cells of many different tissues, including the brain, gastrointestinal tract, and skin. It is also known as CMRF35-like molecule 1 (ISOFORM 3).

CD300LF plays a crucial role in the development and progression of many types of cancer, including CML. Studies have shown that CD300LF is highly expressed in the blood and bone marrow of people with CML. It is alsoabstracted in many scientific journals, and some studies have suggested that it may be a potential drug target for CML.

CD300LF is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four constant (C) regions and one variable (V) region, while the light chains contain one variable (V) region and one constant (C) region. CD300LF is characterized by its constant region, which consists of a variable region that contains a unique amino acid sequence and a variable region that contains a single amino acid residue.

CD300LF has been shown to play a role in many different types of cancer, including CML. For example, some studies have shown that high levels of CD300LF are associated with poor prognosis in people with CML. Additionally, some studies have suggested that CD300LF may be a potential biomarker for CML, as it has been shown to be downregulated in the blood and bone marrow of people with CML.

CD300LF as a Drug Target

One potential way to target CD300LF in CML is to use small molecules or antibodies that can bind to it. This can help to inhibit its function and prevent the growth of cancer cells. Some studies have shown that inhibiting CD300LF with small molecules or antibodies can be effective in treating CML.

Antibodies are one potential way to target CD300LF in CML. Antibodies are proteins that are produced by the immune system to help fight off infections. Some studies have shown that antibodies can be used to target CD300LF and inhibit its function. For example, some researchers have shown that antibodies against CD300LF can be effective in treating CML in animal models.

Another potential way to target CD300LF in CML is to use small molecules that can inhibit its function. Small molecules are drugs that are used to treat a variety of diseases, including cancer. Some studies have shown that small molecules can be used to inhibit CD300LF and prevent the growth of cancer cells. For example, some researchers have shown that inhibiting CD300LF with small molecules can be effective in treating CML in animal models.

CD300LF as a Biomarker

CD300LF has also been suggested as a potential biomarker for CML. Biomarkers are substances that are used to diagnose or monitor a disease. Some studies have shown that measuring levels of CD300LF in the blood or bone marrow can be

Protein Name: CD300 Molecule Like Family Member F

Functions: Acts as an inhibitory receptor for myeloid cells and mast cells (PubMed:15549731). Positively regulates the phagocytosis of apoptotic cells (efferocytosis) via phosphatidylserine (PS) recognition; recognizes and binds PS as a ligand which is expressed on the surface of apoptotic cells. Plays an important role in the maintenance of immune homeostasis, by promoting macrophage-mediated efferocytosis and by inhibiting dendritic cell-mediated efferocytosis (By similarity). Negatively regulates Fc epsilon receptor-dependent mast cell activation and allergic responses via binding to ceramide and sphingomyelin which act as ligands (PubMed:24035150). May act as a coreceptor for interleukin 4 (IL-4). Associates with and regulates IL-4 receptor alpha-mediated responses by augmenting IL-4- and IL-13-induced signaling (By similarity). Negatively regulates the Toll-like receptor (TLR) signaling mediated by MYD88 and TRIF through activation of PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:22043923). Inhibits osteoclast formation. Induces macrophage cell death upon engagement (By similarity)

The "CD300LF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD300LF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7